ClinicalTrials.govpublic full text
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
adenocarcinoma, adenocarcinoma of the gastro-esophageal, her2, dose finding, taxotere (docetaxel), eloxatin (oxaliplatin), xeloda (capecitabine), herceptin (trastuzumab), interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 805632
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.